Human GFAP ELISA Kit (RMEK-0152638)
Cat. No.: RMEK-0152638
Category: ELISA Kits
INQUIRY
1 x 96 tests
Human GFAP ELISA Kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Human GFAP protein in cell culture media and cerebrospinal fluid samples. The technology. Quantitate Human GFAP with 0. 068 pg/mL sensitivity. _x000D_
Product Features
| Species Reactivity | Human |
|---|---|
| Detection Method | Colorimetric |
| Assay Duration | One step assay |
| Assay Time | 1.5 h |
| Assay Type | Sandwich (quantitative) |
| Precision | Intra-Assay-CSF-8-11.1%; Inter-Assay-CSF-3-12.4% |
| Sensitivity | 0.068 ng/mL |
| Range | 0.625 ng/mL - 40 ng/mL |
| Sample Type | Cell culture media, Cerebral Spinal Fluid |
| Recovery | Cell culture media-102-100% - 104%; Cerebral Spinal Fluid-109-108% - 111% |
| Key Features | One-wash 90 minute protocol; Sensitivity: 0.068 ng/mL; Range: 0.625 ng/mL - 40 ng/mL; Sample type: Cell culture media, Cerebral Spinal Fluid; Detection method: Colorimetric; Assay type: Sandwich (quantitative); Reacts with: Human |
Target Information
| Target Symbol | GFAP |
|---|---|
| UniProt ID | P14136 |
| Biomarker of SCs/CSCs | Neural Stem Cells (NSCs) Characterization |
| Function | GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. |
| Cellular Localization | Cytoplasm. Associated with intermediate filaments. |
| Post-transcriptional Modifications | Phosphorylated by PKN1. |
| Involvement in Disease | Defects in GFAP are a cause of Alexander disease (ALEXD). Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. |
Storage & Shipping
| Storage | Store at 2-8°C |
|---|---|
| Shipping | Gel Packs |
| Stability | The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. |
For research use only. Not for clinical use.
